Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the "Company") appointed Dr. Russell Kern as its principal financial officer effective immediately. In connection with the appointment, the Company granted Dr. Kern options to purchase 1,000,000 shares of common stock and increased his salary to $130,000 per year.

Dr. Kern, age 36, has been serving, and will continue to serve, as the Company's Executive Vice President and Chief Scientific Officer. Biographical information about Dr. Kern (including his business experience and family relationships) and information about related person transactions is included in the Company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders, which was recently filed with the Securities and Exchange Commission, under the headings "Director Nominees" and "Related Person Transactions" and is incorporated by reference herein.

© Edgar Online, source Glimpses